Dali Pharmaceuticalco.,Ltd (603963.SS)

CNY 2.96

(-3.27%)

Market Cap (In CNY)

650.31 Million

Revenue (In CNY)

87.26 Million

Net Income (In CNY)

-20.03 Million

Avg. Volume

6.4 Million

Currency
CNY
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
2.28-15.97
PE
-
EPS
-
Beta Value
0.139
ISIN
CNE100002VL4
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Jun Xiang Yang
Employee Count
-
Website
https://www.daliyaoye.cn
Ipo Date
2017-09-22
Details
Dali Pharmaceuticalco.,Ltd researches, develops, produces, and sells pharmaceutical products in China. It develops Chinese and Western medicine injection products of 20 varieties with 44 specifications of the injection drug approval number. The company's products include xingnaojing, shenmai, and astragalus injections, as well as leucocin A and citicoline injections. It also has 31 patents, including 11 invention patents, 16 utility models, and 3 design patents. The company was founded in 1996 and is headquartered in Dali, China.